相关实验视频

Updated: May 9, 2025

Electroconvulsive Seizures in Rats and Fractionation of Their Hippocampi to Examine Seizure-induced Changes in Postsynaptic Density Proteins

Electroconvulsive Seizures in Rats and Fractionation of Their Hippocampi to Examine Seizure-induced Changes in Postsynaptic Density Proteins

Published on: August 15, 2017

在电治疗期间使用文拉法辛与后期服用抗高血压药物有关

Sebastian Karl¹, Jonathan Reinwald, Susanne Berger¹

¹From the Department of Psychiatry and Psychotherapy, Research Group Brain Stimulation, Central Institute of Mental Health, Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany.

The journal of ECT

|April 30, 2025

概括

作为抗抑郁药的文拉法辛 (Venlafaxine) 可能会增加在电治疗 (ECT) 期间需要服用血压药物的需要. 在老年患者和在ECT期间血压升高的患者中,这种风险更高. 临床医生应密切监测患者.

科学领域:

精神病学是一个精神病学.
药理学药理学是指药理学的学科.
心脏病学心脏病学

背景情况:

电疗法 (ECT) 是重度抑郁症的主要治疗方法,通常与抗抑郁药一起使用.
抗抑郁药具有诺亚上腺作用,如文拉法辛,可能会在ECT期间影响血压.
电流疗法可能会导致短暂的血压变化,需要谨慎的药物管理.

研究的目的:

调查文拉法辛是否会增加在电治疗 (ECT) 期间需要服用抗高血压药物的需要.
在ECT期间评估这种关联在高风险患者中,先前存在的高血压.

主要方法:

对患者数据的回顾性分析,比较使用venlafaxine和不使用venlafaxine的ECT会议.
使用混合效应后勤回归来确定需要抗高血压药物的几率.
专注于高风险患者,在ECT期间静脉血压>200 mmHg.

主要成果:

同时服用文拉法辛显著增加了需要在ECT后服用抗高血压药物的几率 (OR,5.46;P = 0.015).
老年患者也显示需要抗高血压药物的几率更高 (OR,3.28;P = 0.019).
分析包括56名患者和1173次ECT治疗,分析了高风险患者的396次治疗.

结论:

在ECT期间使用venlafaxine可能会增加需要服用抗高血压药物的可能性.
这种关联特别适用于高风险的高血压患者.
临床医生应考虑在ECT治疗期间调整文拉法辛剂量或时间.

关键词:

美国欧洲欧洲欧洲欧洲欧洲血压血压血压血压电疗法是一种电疗法.这种高血压,高血压.维纳拉法辛 (venlafaxine) 是一种药物.

更多相关视频

Vagus Nerve Stimulation As an Adjunctive Neurostimulation Tool in Treatment-resistant Depression

Vagus Nerve Stimulation As an Adjunctive Neurostimulation Tool in Treatment-resistant Depression

Published on: January 7, 2019

Pupillary Response as Assessment of Effective Seizure Induction by Electroconvulsive Therapy

Pupillary Response as Assessment of Effective Seizure Induction by Electroconvulsive Therapy

Published on: April 11, 2019

相关概念视频

Electroconvulsive Therapy

Electroconvulsive Therapy

Electroconvulsive therapy (ECT), or shock therapy, remains a critical biomedical intervention for severe, treatment-resistant depression. While its origins can be traced back to Hippocrates' observations that malaria-induced convulsions alleviated mental illness, modern ECT has evolved significantly from its earlier, more primitive applications. First introduced in 1938 by Ugo Cerletti and his colleagues, ECT involves inducing controlled seizures using electrical currents. In its early...

Antiepileptic Drugs: Potassium Channel Activators

Antiepileptic Drugs: Potassium Channel Activators

Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...

Antidepressant Drugs: MAOIs and Other Agents

Antidepressant Drugs: MAOIs and Other Agents

Atypical antidepressants, including bupropion (Wellbutrin), mirtazapine (Remeron), nefazodone (Serzone), trazodone (Desyrel), and vilazodone (Viibryd), offer unique mechanisms of action. Bupropion weakly inhibits dopamine and norepinephrine reuptake, aiding depression treatment and smoking cessation, with a low risk of sexual dysfunction. Mirtazapine enhances serotonin and norepinephrine neurotransmission, leading to sedation, increased appetite, and weight gain. As a result, it helps treat...

Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein

Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein

Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...

Antidepressant Drugs: Tricyclics, SSRIs, and SNRIs

Antidepressant Drugs: Tricyclics, SSRIs, and SNRIs

Tricyclic Antidepressants (TCAs), including Desipramine (Norpramin), Imipramine (Tofranil), Clomipramine (Anafranil), and Amitriptyline (Elavil), inhibit serotonin and norepinephrine reuptake and also block other receptors. They are used for depression, pain conditions, and insomnia. Common adverse effects include anticholinergic effects, sedation, orthostatic hypotension, and weight gain. They have a narrow therapeutic window and so require plasma-level monitoring. Abrupt discontinuation can...

Mania and Antimanic Drugs: Overview

Mania and Antimanic Drugs: Overview

Mania, a psychological condition characterized by elevated mood, increased energy, and reduced sleep need, is part of the bipolar disorder cycle. The exact cause of mania isn't entirely known, but it is thought to be a combination of genetic, environmental, and neurological factors. Bipolar disorder involves alternating manic and depressive episodes. Mood stabilizers like lithium, antipsychotics, and anticonvulsants help manage these episodes. Lithium carbonate is particularly effective as...